Clinical trials: Alzheimer Disease 1
Healthy Volunteers
Bisnorcymserine in Healthy Adult Volunteers
Background: Alzheimer s disease (AD) is a brain disease that impairs memory, cognitive abilities and the ability to function independently. It is the most common cause of dementia in older people.
- Trial name
- NCT01747213
- Testing
- BNC
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institute on Aging (NIA)
Alzheimer Disease, Progressive Supranuclear Palsy
Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity
This is an open-label study without randomisation. All eligible patients will receive two administrations of the investigational imaging agent [18F]PI-2620 at a radioactive dose of 185 MBq, one with high specific activity (≤ 5 µg…
- Trial name
- NCT04715750
- Testing
- [18F]-PI2620
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Life Molecular Imaging GmbH
Obstructive Sleep Apnea, Cognitive Decline
The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study
The Effects of Successful OSA TreatmENT on Memory and AD BIomarkers in Older AduLts (ESSENTIAL) study is a 5-year, multicenter randomized open-label trial that will screen 400 cognitively normal older adults recruited from…
- Trial name
- ESSENTIAL (NCT05988385)
- Testing
- Positive airway pressure, Oral appliance therapy, Positional therapy
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- California Pacific Medical Center Research Institute
Healthy Aging, Alzheimer's Disease
The Feasibility, Safety and Tolerability of VR-based Audiovisual Stimulation
This single-session, within-subject, sham-controlled early feasibility study evaluated the safety, tolerability, and feasibility of delivering 40 Hz audiovisual (gamma sensory) stimulation through a virtual reality (VR) headset…
- Conditions
- Healthy Aging, Alzheimer's Disease, Mild Cognitive Impairment
- Trial name
- CFS (NCT06234930)
- Testing
- Audiovisual stimulation VR system
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Clarity Health Technologies, Inc
Sedentary Behavior, Physical Inactivity
Promoting Physical Activity in Older Hispanic/Latino(a) Adults
In this randomized controlled trial, study staff will randomize 130 Hispanic/Latino adults without dementia and over age 55 from Southern California and from Kaiser Permanente Washington (State) to either the culturally adapted…
- Conditions
- Sedentary Behavior, Physical Inactivity, Alzheimer Disease, Protection Against
- Trial name
- NCT06362824
- Testing
- De Pie Intervention, Active Comparison Group: Healthy Actions And Lifestyles To Avoid Dementia (HALT-AD)
- Where
- 2 sites in United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Preclinical Alzheimer's Disease, Alzheimer Disease
Alzheimer's Tau Platform: Master Protocol
The goal of the Alzheimer's Tau Platform (ATP) is to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with the anti-amyloid monoclonal antibody, donanemab, in adults aged 50-80 with late…
- Conditions
- Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
- Trial name
- ATP (NCT06957418)
- Testing
- AADvac1, Tau2
- Where
- 7 sites in United States
- Volunteers
- 900 people
- Sponsor
- Paul S. Aisen
Aging
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
Background: Some people experience cognitive decline as they age. That is, they lose memory, problem-solving, and other mental abilities.
- Trial name
- NCT07099053
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
Alzheimer's Tau Platform: Regimen A - AADvac1
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early…
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Trial name
- ATP (NCT07167966)
- Testing
- AADvac1, Donanemab
- Where
- 7 sites in United States
- Volunteers
- 450 people
- Sponsor
- Paul S. Aisen
Alzheimer s Disease, Mild Cognitive Impairment
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias.
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment, Healthy
- Trial name
- NCT07169630
- Testing
- 18F-PF974, 18F-florbetaben
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Alzheimer's Disease
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Background: Normal aging, as well as dementias such as Alzheimer s disease, can cause changes in the brain that affect memory, attention, and thinking.
- Trial name
- NCT07721467
- Testing
- Psilocybin, Cognitive Training
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Alzheimer Dementia (AD), Caregiver Burden of People With Dementia
VICA: A Virtual Care Assistant for Dementia Caregivers
This pilot randomized controlled trial evaluates the feasibility and preliminary efficacy of VICA, an AI-powered virtual care assistant that delivers evidence-based education, symptom monitoring, and coaching to informal…
- Trial name
- VICA (NCT07779785)
- Testing
- VICA - Virtual Informal Care Assistant, Education only BPSD mobile app
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Indiana University
Alzheimer's Disease
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants
This study is a randomized, double-blind, dose-escalation, placebo-controlled Phase I clinical trial in healthy participants to evaluate the safety, tolerability, and pharmacokinetics of single intravenous and subcutaneous…
- Trial name
- NCT07889349
- Testing
- SHR 3201 Injection
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Dementia, Agitation
Virtual Reality to Advance Dementia Care and Quality of Life
The goal of this feasibility clinical trial is to learn whether supervised virtual reality (VR) sessions can be safely and practically provided to adults aged 55 years and older with moderate-to-severe dementia who experience…
- Conditions
- Dementia, Agitation, Behavioural and Psychological Symptoms of Dementia, Major Neurocognitive Disorder
- Trial name
- VR-Care (NCT07893678)
- Testing
- Supervised Virtual Reality Sessions
- Where
- 2 sites in Canada
- Volunteers
- 10 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Alzheimer Disease
Use of Socially Assistive Robots for Long Term Care Older Adults With Cognitive Impairment and Apathy
The objective of this study is to demonstrate the impact of a socially assistive robot system on reducing apathy among cognitively impaired older adults residing in long term care facilities.
- Trial name
- NCT05178992
- Testing
- Socially Assistive Robot Activity
- Where
- United States
- Volunteers
- 142 people
- Sponsor
- Vanderbilt University
Alzheimer Disease
[18F]PI-2620 Phase 3 Histopathological Study
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and…
- Trial name
- NCT05641688
- Testing
- [18F]PI-2620
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer Disease, Myasthenia
Presence of Anti-RACH Antibodies and Neurocognitive Disorder in Myasthenic or Alzheimers's Patients.
The purpose of the study is to evaluate if there is a specific association between the presence of anti Rach antibodies in the CSF and the presence of a cogntive disorder in myasthenic patients.
- Trial name
- ARN-MA (NCT06523296)
- Testing
- Adults with Alzheimer's disease, Adults with Myasthenia, Healhty controls
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Alzheimer's Disease (AD)
VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease
This study is to be conducted in participants with early Alzheimer's Disease to test VY7523, a new drug being researched for treatment of Alzheimer's Disease.
- Trial name
- NCT06874621
- Testing
- VY7523
- Where
- 23 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Voyager Therapeutics
Dementia, Alzheimer's Type, Alzheimer's Disease
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants.
- Trial name
- TREMHANCE (NCT07688213)
- Testing
- SAR448851
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 160 people
- Sponsor
- Sanofi
Dementia, Alzheimer Dementia (AD)
Fuzhou Aging Brain Health Initiative
The goal of this observational study is to learn about the pathophysiological characterization and evolutionary patterns of Alzheimer's disease (AD) in older adults in Fujian Province, China.
- Conditions
- Dementia, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Subjective Cognitive Decline (SCD)
- Trial name
- FAITH (NCT07891429)
- Testing
- Fluids biomarker and neuroimaging of AD diagnosis
- Where
- 4 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Fujian Medical University Union Hospital
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry